Citi analyst Yigal Nochomovitz raised the firm’s price target on Syndax (SNDX) to $51 from $46 and keeps a Buy rating on the shares. The firm also added a positive “upside catalyst watch” on Syndax ahead of the PDUFA deadline in relapsed or refractory NPM1-mutated acute myeloid leukemia of October 25. Q2 revenue of about $38M beat the firm’s estimates by greater than 70% and Visible Alpha consensus by about 45%, driven by growth for Revuforj and Niktimvo, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX: